All Drug Discovery Processes articles
-
NewsNew malaria mutations linked to resistance against multiple front-line drugs
Whole-genome sequencing of parasites from Ugandan patients has uncovered a cluster of genetic variants linked to reduced susceptibility to multiple front-line malaria treatments, with researchers warning the mutations are spreading rapidly.
-
ArticleWhat makes a human biospecimen fit for purpose in drug discovery
Human biospecimens can bring drug discovery closer to human disease, but their value depends on far more than the sample itself. We explore the factors that determine how much researchers can learn from them.
-
WebinarMapping the prostate tumour microenvironment with spatial proteomics
As spatial proteomics advances, how can researchers find the complex biology of the prostate tumour microenvironment while preserving spatial context? Hear experts from the University of Surrey share their approach.
-
NewsInsilico launches specialist AI models for drug discovery chemistry
Insilico Medicine has unveiled a suite of compact, domain-trained AI models targeting ADMET prediction, retrosynthesis and target activity across GPCR and kinase panels, claiming state-of-the-art results on more than 70 benchmarks.
-
ArticlePROTACs vs molecular glues: which degrader fits your target?
PROTACs and molecular glues can both remove disease-associated proteins, but choosing between them is not simple. Our new Discovery Toolkit compares the options to help discovery teams choose the right strategy.
-
WebinarWhat it really takes to turn cancer discoveries into new therapies
Five leading cancer researchers from across genomics, proteomics, cell biology, chemical biology and gene therapy dig into what’s driving cancer drug discovery forward and what’s still holding progress back.
-
ArticleHow AI-driven systems biology will reset the starting line for drug development
AI is making drug discovery faster, but can it make it more successful? Discover why combining AI with systems biology could help researchers tackle the biological complexity behind drug failure.
-
ArticleWhy intracellular targets remain a major drug discovery challenge – and how they’re becoming druggable
Many biologically important intracellular targets remain difficult to drug. Dr Rab Prinjha examines how screening within living cells could help tackle them.
-
ArticleWhy single-cell foundation models have underdelivered and what drug discovery needs instead
Foundation models have delivered breakthroughs in protein biology, but single-cell models have struggled to match them. What is holding them back?
-
NewsWhat Google’s AI talent exodus could mean for future drug discovery
The departure of leading AI researchers from Google to found Discovery Loop raises important questions about the future direction of artificial intelligence in scientific research and drug development.
-
NewsInsilico Medicine launches AI drug discovery benchmarking platform
Insilico Medicine has unveiled a benchmarking platform designed to assess whether AI models can perform genuine drug discovery tasks, using decontaminated real-world datasets and proprietary validated programmes to move beyond inflated benchmark scores.
-
NewsResearchers develop AI system to accelerate tuberculosis drug discovery
Researchers at Texas A&M have developed AI-driven platforms to help scientists navigate the bottlenecks of tuberculosis drug discovery, from eliminating nuisance compounds to unlocking years of archived research data.
-
ArticleAI’s promise and practical limits in drug discovery
From ChatGPT to AI agents and world models, where is AI really heading in drug discovery? Dr Raminderpal Singh explains what researchers should focus on now.
-
WebinarOligonucleotide therapeutics safety considerations across drug development
As oligonucleotide therapeutics continue to advance, their safety assessment presents challenges that differ from traditional drug modalities. Discover how nonclinical safety studies, evolving regulatory expectations and real-world case examples can help you navigate these challenges with greater confidence.
-
NewsELRIG appoints two industry veterans to their Scientific Advisory Board
Not-for-profit drug discovery organisation ELRIG has appointed Dr Hitesh Sanganee and Dr Marcus Schindler to its Scientific Advisory Board, bringing decades of combined R&D, venture investment and pharmaceutical leadership expertise to help shape the organisation’s future scientific programmes.
-
WebinarMeeting ethical & regulatory requirements when using human biological specimens
Whether you source, purchase or work with human biospecimens, understanding today’s ethical and regulatory expectations is essential. Join this webinar to explore informed consent, privacy and the principles that support responsible research.
-
WebinarBuilding better therapeutic antibodies: the science, progress and problems to solve
As therapeutic antibodies become more complex, where is the field making real progress and which problems are proving hardest to solve? Hear leading experts share their perspectives.
-
ArticleAI’s real value in drug discovery may be choosing the right experiment
AI is becoming more capable, but its value still depends on the data, questions and decisions behind it. Where is it genuinely improving drug discovery and where do the limitations remain?
-
NewsLargest chemical reactions database launched to boost AI drug discovery
Researchers at the University of Michigan have assembled a database of more than 50,000 chemical experiments, offering AI systems an unprecedented resource to accelerate drug discovery and reduce reliance on scarce precious metal catalysts.
-
ArticleSmall tags, big advances: studying endogenous proteins in their native context
By combining CRISPR knock-in with small peptide tags, researchers can study proteins in their native cellular context, generating more predictive data for translational drug discovery.